The Trump administration's CMS Administrator Dr. Mehmet Oz outlines a comprehensive strategy to address rising pharmaceutical costs through industry collaboration and regulatory oversight. With 26 major drug manufacturers committing to pricing reforms, the initiative aims to increase medication affordability for Medicare beneficiaries while simultaneously tackling fraudulent practices within the healthcare system. This multi-faceted approach combines corporate partnerships with enhanced compliance measures to ensure sustainable cost reduction.

Summary auto-generated by AI from the original publisher's content. Editorial standards.